Ketamine News and Research

RSS

Study compares two drug combinations for use as deep sedation during oral surgery

The ideal sedative for oral surgery should make the patient comfortable during the surgery and should wear off quickly enough that the patient can leave the dental chair soon after the procedure. Finding the best plan of anesthetic treatment is essential to the success of dental procedures such as the extraction of wisdom teeth.

12 Oct 2012

Ketamine can help improve brain function in Rett syndrome mice

A promising study out today in the prestigious Journal of Neurosciences showed that in a mouse model of Rett syndrome, researchers were able to reverse abnormalities in brain activity and improve neurological function by treating the animals with an FDA-approved anesthesia drug, ketamine.

4 Oct 2012

No aping around after anesthetic combination

A combination of medetomidine and ketamine administered intramuscularly to chimpanzees, orangutans, and gorillas results in reliable immobilization for both the animals and personnel handling them, report researchers.

15 Aug 2012

Scientists discover biological marker that may help identify patients’ response to antidepressants

Scientists have discovered a biological marker that may help to identify which depressed patients will respond to an experimental, rapid-acting antidepressant. The brain signal, detectable by noninvasive imaging, also holds clues to the agent's underlying mechanism, which are vital for drug development, say National Institutes of Health researchers.

7 Aug 2012

Ketamine reduces suicidal thoughts in patients with bipolar depression

Bipolar disorder is a serious and debilitating condition where individuals experience severe swings in mood between mania and depression. The episodes of low or elevated mood can last days or months, and the risk of suicide is high. Antidepressants are commonly prescribed to treat or prevent the depressive episodes, but they are not universally effective. Many patients still continue to experience periods of depression even while being treated, and many patients must try several different types of antidepressants before finding one that works for them.

31 May 2012

FDA grants Fast Track designation to EpiCept's AmiKet

EpiCept Corporation announced today that AmiKet (amitriptyline 4%, ketamine 2% cream) has been granted Fast Track designation by the U.S. Food and Drug Administration.

10 Apr 2012

Scientists explore number of strategies to prevent anesthesia-induced injury in infants

Recent clinical studies have shown that general anesthesia can be harmful to infants, presenting a dilemma for both doctors and parents. But new research at Wake Forest Baptist Medical Center may point the way to treatment options that protect very young children against the adverse effects of anesthesia.

29 Mar 2012

EpiCept fourth quarter revenue decreases to $0.2 million

EpiCept Corporation today announced operating and financial results for the fourth quarter and full year ended December 31, 2011, and provided an update on the Company's key business initiatives.

29 Feb 2012

ICN Food List for interstitial cystitis/bladder pain syndrome patients

When one cup of coffee, tea or cranberry juice can trigger days of pain and/or bladder discomfort, interstitial cystitis, overactive bladder and other urology patients often develop an unhealthy fear of food. A new iPhone and iPad application, (ICN Food List) seeks to change that by giving patients an easy to use food list and database that they can use while shopping and eating out at restaurants.

13 Feb 2012

EpiCept seeks FDA Fast Track designation for AmiKet to treat CIPN

EpiCept Corporation today announced that it has filed for Fast Track designation for AmiKet(amitriptyline 4%, ketamine 2% cream) for the treatment for chemotherapy-induced peripheral neuropathy (CIPN) with the U.S. Food and Drug Administration.

7 Feb 2012

EpiCept receives FDA approval to commence AmiKet Phase III trial for CIPN

EpiCept Corporation today announced that at a meeting earlier this week with the U.S. Food and Drug Administration (FDA), the Company was granted permission to initiate immediately the Phase III clinical development of AmiKet.

23 Dec 2011

General anesthesia can cause cognitive impairment in children

General anesthesia administered to the developing animal brain depresses much needed neuronal activity and communication resulting in long-lasting cognitive impairment, according to an article published in the August issue of Current Opinion in Anesthesiology.

12 Sep 2011

New sensor can detect 'date rape' drugs

Smart women know it's wise to beware when out at a bar or club - there could be more than just alcohol in that cocktail. Psychoactive substances classified as "date rape" drugs can be dropped into an unsuspecting victim's drink, rendering her barely conscious and susceptible to sexual assault.

10 Aug 2011

Naurex commences GLYX-13 Phase II trial in treatment-resistant depression

Naurex Inc., a clinical-stage company developing innovative treatments to address unmet needs in psychiatry and neurology, today announced that it has initiated a Phase II clinical trial of its lead compound GLYX-13.

22 Jun 2011

Fast-acting antidepressant effect of ketamine

UT Southwestern Medical Center scientists are shedding new light on why the anesthetic drug ketamine produces a fast-acting antidepressant response in patients with treatment-resistant depression.

17 Jun 2011

Multiple exposures to anesthesia may increase risk of ADHD, learning disabilities in young children

Infants and very young children who are exposed to anesthesia may experience higher rates of learning disabilities and cognitive difficulties than children who are not exposed to anesthesia, according to research and emerging data presented during the SmartTots: Pediatric Anesthesia Neurotoxicity panel at the International Anesthesia Research Society annual meeting in Vancouver, B.C.

30 May 2011

Evidence of damaged baby brains & inadequate anesthetic induced sleep: Conference updates

According to new studies commonly used anesthetics may be causing brain damage in people, especially babies who receive them while their brains are still developing.

15 May 2011

Naurex announces completion of $18 million Series A financing

Naurex Inc., a clinical-stage company developing innovative treatments to address unmet needs in psychiatry and neurology, today announced the completion of an $18 million Series A financing led by Adams Street Partners and Latterell Venture Partners.

11 May 2011

Comprehensive book on chronic pain and addiction

Up to date and comprehensive, this book is relevant to all professionals engaged in the care of patients with chronic pain or addiction and all others interested in these contemporary issues, particularly non-clinicians seeking clarity in the controversy over the best approach to patients with chronic pain.

6 Apr 2011

Positive results from EpiCept NP-1 Phase IIb trial in patients with CPN

EpiCept Corporation today announced positive results from a Phase IIb trial evaluating the efficacy and safety of EpiCept NP-1 in chemotherapy-induced peripheral neuropathy. EpiCept NP-1 is a topical analgesic cream containing two FDA-approved drugs, amitriptyline and ketamine, in development for the relief of pain from various peripheral neuropathies.

7 Feb 2011